Pentagastrin and the Gastric Acid Test: A Diagnostic Peptide's History

The clinical question

For much of the twentieth century, doctors needed a reliable way to measure how much acid the stomach could produce. Excess acid pointed toward ulcer-prone states and, in extreme cases, hormone-secreting tumors; too little suggested other disorders. To measure maximal capacity, clinicians needed a standardized stimulus that would reliably switch on acid secretion. Pentagastrin was designed to be that stimulus. This use case is educational and describes a largely historical diagnostic procedure.

What pentagastrin is

The body's own hormone gastrin is released from G-cells of the stomach and drives acid secretion — partly by prompting ECL cells to release histamine, which in turn stimulates the acid-producing parietal cells. Gastrin's biological activity resides in its C-terminal end.

Pentagastrin is a synthetic pentapeptide that reproduces that active C-terminal sequence. Because it contains just the business end of the hormone, it behaves like gastrin at the receptor and reliably stimulates acid output — a convenient, well-defined drug for a test rather than a treatment. It was marketed under the name Peptavlon.

How it was used

Pentagastrin had two main diagnostic roles:

Gastric acid secretion testing. Given by injection, pentagastrin stimulated the stomach to secrete acid, allowing clinicians to measure maximal (peak) acid output. This helped assess conditions of acid over- or under-production and, historically, to evaluate suspected gastrin-driven states.

Calcitonin provocation. Separately, pentagastrin was used to stimulate calcitonin release as a provocation test in medullary thyroid cancer — a tumor of the calcitonin-producing cells of the thyroid — and in related evaluations. A rise in calcitonin after pentagastrin helped detect or monitor the disease.

Why it faded

Pentagastrin is now largely discontinued in many markets, and in the United States it is best regarded as research-only / no longer routinely available. Two things drove its decline. First, medicine changed how it approaches acid-related disease: powerful acid-suppressing drugs and better tests (including blood gastrin measurement and endoscopy) reduced the need for provocative acid studies. Second, for thyroid cancer, sensitive basal calcitonin assays now allow diagnosis and monitoring without a provocation agent in most cases, so the pentagastrin-stimulated test has been largely superseded.

Where it fits today

Pentagastrin's story is a useful lesson in how diagnostics evolve. A cleverly minimal peptide — just the active fragment of a hormone — solved a real problem for decades, then became unnecessary as both therapy and measurement advanced. It is included here for historical and educational context rather than as a current recommendation.

Its underlying biology remains relevant: gastrin excess is central to gastrin-secreting tumors such as those causing Zollinger-Ellison syndrome, where uncontrolled acid production causes severe ulcers. Understanding how a synthetic gastrin mimic switches on acid secretion helps make sense of how the natural hormone drives disease when it is overproduced.

The bottom line

Pentagastrin was a synthetic gastrin fragment used to provoke gastric acid secretion and, separately, to stimulate calcitonin in thyroid cancer testing. It is now largely discontinued, replaced by newer tests and treatments. Treat it as a historical diagnostic peptide, not a current clinical tool.

> This use case is educational and not medical advice. Pentagastrin is largely discontinued; any diagnostic evaluation should follow current, clinician-directed testing.